Advancing Treatment of
Bladder Cancer
A Continuing Medical Education Activity sponsored by InforMEDical Communications, Inc.
InforMEDical Communications, Inc. •
83 Acton Street • Carlisle, MA 01741
tel: 978-318-9582 • fax: 978-318-9583 • email: info@informedicalcme.com
CME Information
Up to 2 hours of AMA PRA Category 1 Credit™
Release date: July 2008 Valid through: July 2009
Course Material: Online Only
Receiving CME Credit
To receive online CME credit for this activity, read the full activity then click below to complete the registration, test and evaluation.
You will have 2 opportunities to answer the questions correctly. Then you will be shown answers to any questions answered incorrectly, to be sure you understand the material. You will be able to print your CME certificate immediately following completion of the test and evaluation.
Target Audience
This educational activity is intended for oncologists, urologists and other medical professionals who assess, treat and counsel patients with bladder cancer.
Educational Objectives
Following completion of this activity, participants should be able to:
- Assess appropriate use of systemic chemotherapy in the management of muscle invasive bladder cancer.
- Discuss optimal approaches to treating superficial bladder cancer, including BCG + interferon and addressing patients who fail BCG therapy.
Educational Need
A variety of classes of novel systemic therapies are entering development for the treatment of bladder cancer, fueled by new insights into cancer biology and possible approaches to blocking its progression. As the range of drug targets and mechanisms for addressing these targets proliferate, it has become increasingly important for oncologists and surgeons who have experience in treating this disease to more effectively share information and expertise, and to advance specific recommendations for research and patient care.
Sponsorship and Accreditation
This CME activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) by InforMEDical Communications, Inc. InforMEDical is accredited by the ACCME to provide continuing medical education for physicians and takes responsibility for the content, quality and scientific integrity of this CME activity.
Educational Grant Support
This CME activity is supported by educational grants from Bristol-Myers Squibb Company, Eli Lilly and Company and Schering Corporation.
Credit Designation
InforMEDical designates this continuing medical education activity for up to 2 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Disclosure
The program faculty disclosed the following financial relationships: Colin P. N. Dinney: Paid consultant: Schering Plough, Novartis, Bristol Myers Squibb; Research support: AstraZeneca, GlaxoSmithKline; Speakers Bureau: SciMed, Abbot/Vysis. Maha H. A. Hussain: Paid consultant: Lilly; Research funding: Pfizer.
This educational activity may contain discussion of published and/or investigational uses of agents, devices or diagnostics tools that have not been approved for use by the US FDA. The opinions expressed in the activity are those of the authors, and do not reflect those of the industry supporters or CME sponsor. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, contradictions and warnings. Participants/readers should appraise the information presented critically and are encouraged to consult appropriate resources for any product, device or diagnostic tool mentioned in this activity.